Company ProfilePremium

CG Invites Co., Ltd.

Company Profile Analysis

Ticker: 083790.KQ인바이츠 to June 2023. S&P Global

ESOMAR 23 Corporate BadgeISO Certifications Badge
CG Invites Co., Ltd. - Company showcase

Year Founded & Workforce

2000

71 Employees

CG Invites Co., Ltd. logo

CG Invites Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

CG Invites Co., Ltd. Overview

CG Invites is a small-cap KOSDAQ company in the middle of a deliberate transition. It is moving from first-generation Korean drug-discovery biotech (CrystalGenomics, the first company listed on KOSDAQ under the technology-evaluation special listing track in 2006) to a data-driven digital healthcare business. The transition is directed by its private-equity controlling shareholder, New Lake Alliance. The legacy asset base includes Acelex (polmacoxib), approved in 2015 as Korea's 22nd domestically developed new drug, and a clinical oncology pipeline anchored by ivaltinostat (CG-745, HDAC inhibitor, US Phase 2 in metastatic pancreatic cancer) and Korean rights to camrelizumab (PD-1). Since 2023, management has sold non-core holdings, cut R&D spending sharply, and consolidated externally sourced businesses. In FY2025 these were AI healthcare solutions, heating patches, automation equipment and genomic analysis, which together accounted for about 92% of revenue. The investment case now depends on whether the "Invites Loop" AI health platform generates revenue, including through a September 2026 China license. It also depends on resolving a US legal dispute with the founder over the ivaltinostat subsidiary, and on refinancing a negative working-capital position.


Company's own description

Third-party filings indexes summarize the company's self-description as follows. CG Invites is a biopharmaceutical company focused on digital genomics and personalized medicine, with four activity areas:

  1. Genomics, using whole-genome sequencing.

  2. mRNA-based personalized cancer vaccines.

  3. Digital therapeutics (software-based interventions).

  4. Chemical and biological drug development, covering oncology and inflammation (Acelex, ivaltinostat, camrelizumab).

Management has described the change in direction more explicitly. A company official told Dealsite TV in May 2026 that since joining the Invites ecosystem in 2023, the company has been shifting toward digital healthcare. The official said the legacy pipeline cannot be wound down all at once, but the digital-healthcare direction has become concrete since 2025.

Independent characterization

On the evidence of FY2025 revenue composition, CG Invites is now best described as a diversified small-cap healthcare holding-type company. It has a residual drug-development pipeline and a nascent AI health-data platform. FY2025 consolidated revenue by product, as reported in the DART annual report and cited by Dailypharm on 8 May 2026:

  • AI healthcare solutions: KRW 8.2bn (30.7%)

  • Heating patches (hot packs): KRW 7.2bn (27.1%)

  • Automation equipment: KRW 4.7bn (17.5%)

  • Genomic analysis and other: KRW 4.6bn (17.4%)

  • Arthritis analgesic/anti-inflammatory (Acelex): KRW 1.7bn (6.3%)

Prescription pharmaceuticals therefore contributed only about 6% of revenue. Standalone (parent-only) revenue in FY2025 was about KRW 11.8bn (Dealsite, 28 Sep 2026). This implies that roughly KRW 15.6bn, or about 57% of consolidated revenue, came from consolidated subsidiaries and businesses incorporated through acquisition or merger. Dealsite TV (May 2026) attributes the revenue growth to externally incorporated businesses and mergers rather than to in-house drug development. The specific entities that brought the heating-patch and automation-equipment businesses are not identified in the sources reviewed.

Business and revenue model

Revenue streamModelEvidence
Acelex (polmacoxib 2mg)Product sales (prescription drug, Korea), plus pursuit of export licensing (Russia in negotiation as of Jul 2025)Dailypharm; Dealsite
AI healthcare solutions / Invites LoopSolution/service revenue in Korea, plus technology licensing abroad: China exclusive license with a 5% running royalty on net sales (Sep 2026); planned US licensing via a New Lake Singapore hubDailypharm; Dealsite
Genomic analysis (NGS testing)Testing-service fees. The service launched in April 2025 and received College of American Pathologists (CAP) accreditation in May 2025.Financial News; Dailypharm
Heating patchesConsumer/industrial product salesDailypharm (DART segment data)
Automation equipmentEquipment salesDailypharm (DART segment data)
Pipeline out-licensingUpfront payments and milestones (historically CG-806 with Aptose, worth up to about KRW 487bn in total). Dealsite TV reports that technology-fee income has dried up.Dailypharm; Dealsite TV

Value-chain position and customers

Pharmaceuticals: originator and licensor. Acelex is sold to the Korean prescription market (hospitals and clinics). Clinical development is done through CROs and outsourced research, which was cut from KRW 3.6bn in 2024 to KRW 0.5bn in 2025 (Dailypharm).

Digital health: platform/IP owner and licensor. The company acts as licensor through joint ventures (VISTA Invites Digital Ward Ltd, Hong Kong) and intends to keep IP-holder status for US expansion via New Lake Singapore (Dealsite, Jan 2026).

Customer types: hospitals and health-screening institutions (for example, the KMI partnership of Jun 2026), corporate health programs and insurers (via VISTA in China), pharmaceutical licensees, and consumer and industrial buyers for heating patches and automation equipment.

End-markets: Korean prescription NSAIDs, oncology (pancreatic cancer, NSCLC, hematologic cancers), precision genomics, AI preventive healthcare and chronic-disease management, China digital health, and consumer warming products.

Strategy

Stated strategy (paraphrased from management statements)

When joining the Invites ecosystem in June 2023, management set out three pillars, which co-CEO Oh reaffirmed in July 2025:

  1. Selection and focus in the drug pipeline. Concentrate on camrelizumab and ivaltinostat, with oncology as the therapeutic focus across small molecules, genomics and digital therapeutics. Add an open in-licensing platform with biotech funds.

  2. Sell non-core assets to fund clinical investment without further equity raises.

  3. Install a new growth engine in data-driven, personalized digital healthcare.

Plus a shareholder-friendly, ESG-oriented governance commitment (Dailypharm, Jun 2023).

The company's stated long-term ambition is an enterprise value of KRW 1 trillion (Dailypharm, Nov 2024), against a current market capitalization of about KRW 67bn.

Initiatives announced in the last 24 months

DateInitiativeDetail / targets
Apr 2025Genomic testing service launchExpected to contribute from Q2 2025 (Financial News)
May 2025CAP accreditation for NGSSupports international credibility of testing
May 2025Personalized cancer vaccineASCO 2025 data with HLB; colorectal and lung indications; clinic entry as early as early 2027
Jul 2025Acelex export pivotNegotiations with a Russian pharmaceutical company
Sep 2025Guam hospital (GRMC)Largest shareholder acquired control. The plan is a smart hospital and US digital-health beachhead combining HealthConnect solutions with genomic AI services (Dailypharm, May 2026).
Jan 2026Singapore hubUS licensing of Invites Loop via New Lake Singapore, to limit direct exposure to US regulatory, litigation and tax risk
H1 2026K-Digital Healthcare AllianceLaunched by the Invites ecosystem; 55 participating organizations (Dealsite)
Jun 2026KMI partnershipJoint program with Korea Medical Institute (8 screening centers, about 1.5M screenings a year) for global expansion of K-digital healthcare
Jun 2026No reverse stock splitManagement chose to prove value through business results instead. All-employee stock options planned.
Sep 2026China entryVISTA JV (17 Sep) and exclusive license to VIDW (28 Sep): 5% royalty, technology valued at about USD 6.88M. Leverages VISTA's network: Beijing clinic (~80,000 outpatients a year), Shenzhen clinic (~20,000 a year), about 30 corporate medical facilities, corporate clients including Huawei, CNPC, CNOOC, Shanghai Disneyland and Volkswagen China, and about 60 insurers.
2024–2026e-CRO platformBuilding a decentralized clinical trial platform (Dailypharm)

Guidance and medium-term targets

  • No quantitative revenue or margin guidance is disclosed in the sources reviewed.

  • Management expected digital healthcare to monetize in earnest in H2 2026 (Dealsite, Jun 2026).

  • Medium-term target: an enterprise value of KRW 1 trillion (aspirational, no date).

  • ESG and emissions commitments: none disclosed.

Products & Services

Commercial pharmaceuticals

Acelex (polmacoxib 2 mg)

Description: Oral NSAID for osteoarthritis pain and inflammation. Polmacoxib is described as a selective COX-2 inhibitor with carbonic anhydrase affinity.

Approval/launch: Approved and launched in Korea in 2015 as Korea's 22nd domestic new drug (Dailypharm).

Target customer: Prescribers treating osteoarthritis in Korea, with export markets being pursued.

Commercial performance: KRW 2.5bn in launch year 2015 (IB Tomato). KRW 1.7bn in FY2025, equal to 6.3% of revenue (Dailypharm). Co-CEO Oh Soo-yeon acknowledged weak sales due to limited sales and marketing capability and said the company was pivoting to exports, with negotiations under way with a Russian pharmaceutical company (Dealsite, Jul 2025).

Line extension: A polmacoxib/tramadol hydrochloride combination appears in Synapse's pipeline listing.

Pricing: Not publicly disclosed.

Clinical pipeline — oncology

AssetMechanismIndication(s)Stage (latest reported)Partner / structureSource
Ivaltinostat (CG-745)HDAC inhibitor (HDAC 1, 2, 3, 6, 10)Metastatic pancreatic ductal adenocarcinoma (maintenance with capecitabine after ≥4 months of fluoropyrimidine/FOLFIRINOX first-line therapy without progression)Phase 2 randomized portion (NCT05249101), target 52 patients, primary endpoint PFS; about 20 US hospitals (Jan 2026)CG Pharmaceuticals (US)PR Newswire; Dealsite; Dailypharm
IvaltinostatHDAC inhibitorMyelodysplastic syndromePhase 2 (per S&P description)—StockAnalysis/S&P
IvaltinostatHDAC inhibitorAML, hepatocellular carcinomaPreclinical—StockAnalysis/S&P
IvaltinostatHDAC inhibitorFibrotic and metabolic diseasesPhase 1 (per S&P)—StockAnalysis/S&P
Camrelizumab (SHR-1210)Anti-PD-1 monoclonal antibody (originated in China)Non-squamous NSCLC, EGFR/ALK wild-type, stage IIIB–IVKorean bridging study (described as Phase 3 by S&P). 35 patients enrolled at 8 sites as of Jan 2026; Samsung Medical Center added as a site.Korean rights held by CG InvitesSynapse; Dealsite; Dailypharm
Luxeptinib (CG-806)Dual FLT3/BTK multi-kinase inhibitorAML, CLL, non-Hodgkin lymphomaPhase 1 historically. Not in active development per Aptose's 2026 merger filing.Licensed to Aptose (2016; up to ~KRW 487bn). Edaily (Oct 2026) lists it among licensed Korean assets returned in 2026.Dailypharm; Edaily/Nate
Personalized neoantigen cancer vaccine (mRNA-based)Patient-specific neoantigen immunizationColorectal cancer, lung cancerPreclinical. Clinical entry targeted as early as early 2027 (Jan 2026 briefing).Collaboration data with HLB presented at ASCO 2025Dealsite; Dailypharm

Ivaltinostat clinical detail: In Phase 1b, 28 patients with locally advanced or metastatic PDAC who had received at least one prior line of therapy were dosed at 60, 125 and 250 mg/m² (days 1 and 8). Dosing was combined with capecitabine at 1,000 mg/m² twice daily on days 1–14 of each 21-day cycle. No serious adverse events related to ivaltinostat occurred in any cohort (CGP, Jan 2025). The Safety Review Committee set the RP2D at 250 mg/m² (Nov 2023). Under the current dispute, CG Invites reportedly receives no formal notification of trial results from CGP (Dailypharm, May 2026).

Clinical pipeline — anti-infective and inflammation

AssetMechanismIndicationStage (per S&P description)
Nilofabicin (CG-549)FabI inhibitor (bacterial fatty-acid synthesis)MRSA infectionsPhase 1
CG-650Anti-inflammatoryOsteoarthritisPhase 1
CG-651Anti-inflammatoryNeuropathic painPhase 1
CG-652Anti-inflammatoryRheumatoid arthritisPhase 1
GSK3 inhibitorsKinase inhibition—Listed by Synapse

In June 2024 the company said it would concentrate on camrelizumab and ivaltinostat and had halted development of other candidates. Those could resume if circumstances such as research funding changed (Dealsite, Jun 2024). The S&P stage descriptions above may therefore overstate current activity.

Digital healthcare and genomics

Invites Loop (인바이츠 루프)

Description: An AI-based personalized integrated health-management platform. It combines genomic data, health-screening data and lifestyle data to predict health status in real time. AI agents intervene around the clock across prevention, treatment and recovery in a continuous "loop."

Claimed capability: Prediction of 35 chronic diseases, including 11 cancers, with stated accuracy above 83%.

Components: Invites Loop operating system and Integrated Risk Score (IRS) technology.

Commercialization: In Korea, revenue is booked as AI healthcare solutions (KRW 8.2bn in FY2025). In China, an exclusive license to VIDW (Sep 2026) was valued at about USD 6.88M, with a 5% net-sales royalty. In the US, licensing is planned via the New Lake Singapore hub (Jan 2026).

Pricing: Not publicly disclosed.

Genomic analysis / NGS testing services

  • Launched April 2025. CAP accreditation for NGS testing announced May 2025.

  • Revenue: KRW 4.6bn in FY2025, combined with "other."

Digital therapeutics

  • Named as a focus area in company descriptions. No named product or regulatory status is disclosed in the sources reviewed.

Non-healthcare product lines

Product lineFY2025 revenue (KRW Bn)Detail
Heating patches (hot packs)7.2Brand names, manufacturing location and originating entity not disclosed in sources reviewed
Automation equipment4.7Product types and originating entity not disclosed in sources reviewed

Financial Narrative

All figures are consolidated, from S&P Global Market Intelligence via StockAnalysis.com (financial data last updated 14 Aug 2026; balance sheet as of 31 Mar 2026), unless noted. Ratios are computed by the author from these figures.

Income statement

Dividends: no dividend appears in the data reviewed, and Simply Wall St scores dividends 0/6. This is consistent with the accumulated deficit.

Latest twelve months (TTM to 30 Jun 2026): revenue KRW 30,110M (+185.5% YoY), gross profit −KRW 4,594M, operating income −KRW 24,304M, EBITDA −KRW 17,580M. Net income attributable was +KRW 429M (EPS KRW 5.58). The positive TTM net income came from equity-method gains (KRW 12,887M), a tax credit (KRW 7,923M), losses absorbed by minority interests (KRW 9,178M) and discontinued operations (+KRW 1,748M). Operations remained deeply loss-making.

Margins and growth

Revenue CAGR (computed): FY2021→FY2025 is −10.3% a year, distorted by the Hwail deconsolidation in FY2022. FY2022→FY2025 is +85.1% a year, driven by acquisitions and consolidation.

Commentary:

FY2021–FY2022: The 89.8% revenue drop reflects the end of Hwail Pharmaceutical's consolidation after the 2020–2021 sell-down. Operating losses widened from KRW 6.8bn to KRW 23.1bn once Hwail's profitable API revenue was gone.

FY2023–FY2024: Under New Lake control, losses peaked at KRW 48.9bn (FY2023) and KRW 51.5bn (FY2024) attributable. FY2023 included a KRW 20.7bn loss on sale of investments and KRW 15.8bn of other non-operating losses. FY2024 included KRW 14.4bn of asset writedowns. R&D peaked at KRW 11.3bn in FY2024, equal to 156% of revenue.

FY2025 inflection: Operating loss narrowed by 40% to KRW 23.6bn. SG&A roughly halved (KRW 23.7bn to KRW 12.3bn) and R&D fell 61% to KRW 4.4bn. Within R&D, outsourced research fell 84.9% (KRW 3.6bn to KRW 0.5bn) and R&D personnel cost fell 58.3% (KRW 1.6bn to KRW 0.7bn) (Dailypharm). Attributable net loss narrowed to KRW 3.5bn mainly through below-the-line items. Equity-method income swung from −KRW 5.5bn to +KRW 9.9bn, there was a KRW 7.9bn tax benefit, and KRW 9.0bn of losses were attributed to minority interests.

Quality of earnings: Gross profit is negative and EBITDA remains about −KRW 17bn. The reported improvement in net income is therefore not yet evidence of operating viability.

Balance sheet

Data note: FY2025 total equity (KRW 129,201M) exceeds common equity plus minority interest (KRW 118,675M) by about KRW 10.5bn in the S&P dataset. The difference is unexplained in the source.

Latest interim:

  • 31 Mar 2026: total debt KRW 56,944M, of which short-term debt KRW 17,636M and current portion of long-term debt KRW 37,200M. Cash and short-term investments KRW 17,424M. Working capital −KRW 47,271M. Common equity KRW 100,681M (BVPS KRW 1,309).

  • 30 Jun 2026: cash and investments KRW 9,391M, total debt KRW 45,438M, net debt KRW 36,047M (S&P via StockAnalysis).

Commentary:

Liquidity erosion: Cash and short-term investments fell 84% from KRW 122.5bn (FY2021) to KRW 19.6bn (FY2025) and KRW 9.4bn (Jun 2026). A KRW 50bn convertible bond was entirely put back early in 2023, according to IB Tomato. Its attribution to CG Invites in that multi-company article should be confirmed against DART.

Debt maturity wall: The entire KRW 37.2bn of long-term debt moved to current liabilities in FY2025, and short-term debt rose to KRW 17.6bn in Q1 2026. Working capital is deeply negative. Simply Wall St flags less than one year of cash runway.

Asset base: Land (KRW 64.2bn) and buildings (KRW 55.1bn) account for most of PP&E. Land rose from KRW 41.7bn to KRW 67.6bn and buildings from KRW 49.9bn to KRW 58.2bn in FY2024. These assets are a potential source of refinancing collateral or sale proceeds.

Acquisitive build-up: Goodwill rose from zero (FY2023) to KRW 3.2bn (FY2024), KRW 7.4bn (FY2025) and KRW 10.3bn (Mar 2026). This corroborates the press accounts of externally incorporated businesses.

Cash flow

TTM to Jun 2026: OCF −KRW 3,361M, capex −KRW 1,263M, FCF −KRW 4,624M. The cash burn has improved materially.

Dividends paid: none recorded in the data reviewed.

Buybacks: A company official told Bizhankook that KRW 8.5bn of shares had been bought since October 2024 to defend the share price. The S&P balance sheet shows zero treasury stock from FY2024 onward.

Funding sources, FY2023–FY2024: Asset disposals funded the cash burn. These included the Pangyo HQ (KRW 34.9bn), the Hwail stake (KRW 12.5bn) and the PanGen stake (KRW 9.3bn). Dailypharm reports total non-core disposals generating KRW 56.8bn of R&D funding.

Ratios (computed, year-end balances)

ROIC: negative throughout, because operating income is negative. The ratio is not meaningful.

Net debt/EBITDA: not meaningful, because EBITDA is negative.

Working-capital ratios: FY2022–FY2024 figures are distorted by tiny revenue bases and year-end consolidation of acquired receivables and inventories. They should not be read as operating trends.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business line (KRW Mn)FY2025

AI healthcare solutions

8,200

Heating patches (hot packs)

7,200

Automation equipment

4,700

Genomic analysis and other

4,600

Arthritis analgesic/anti-inflammatory (Acelex)

1,700

Total consolidated revenue

27,391

Business line share of revenue (%)

FY2025

AI healthcare solutions

30.7

Heating patches

27.1

Automation equipment

17.5

Genomic analysis and other

17.4

Acelex

6.3

Revenue by Segment

Metric (KRW Mn)FY2025

Consolidated revenue

27,391

Standalone (parent) revenue, approx.

11,800

Implied revenue from consolidated subsidiaries, approx.

15,591

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Group Entities

EntityRelationshipStatus / source

CG Pharmaceuticals, Inc. (Orinda, California, USA)

US clinical subsidiary developing ivaltinostat

CG Invites states it holds 100% and controls the board (Dailypharm, Oct 2024). CGP's own Jan 2025 release describes CGP as an "independent entity" since 2024 after licensing ivaltinostat. Control is contested in US litigation.

VISTA Invites Digital Ward Limited (VIDW), Hong Kong

Joint venture with VISTA Clinic Limited; licensee of Invites Loop for mainland China

CG Invites is a shareholder (stake not disclosed). Formed 17 Sep 2026 (Dealsite).

Crystal Bioscience

Subsidiary (100% in 2023)

Dailypharm Aug 2023.

Macaon Biotherapeutics

Subsidiary (52.3% in 2023)

Dailypharm Aug 2023.

Invites Ventures (Seoul, founded 2019)

Listed as affiliate/subsidiary

PitchBook.

BexPharm Healthcare (Seoul, founded 1998)

Listed as affiliate/subsidiary

PitchBook; Citeline.

Palkion

Listed as related entity

Citeline.

Guam Regional Medical City (Dededo, Guam)

Management control acquired by CG Invites' largest shareholder (Sep 2025). PitchBook lists it as a subsidiary of CG Invites.

—

Divested: Hwail Pharmaceutical, PanGen Biotech, Huons Life Sciences (ex-Crystal Life Sciences)

Former affiliates/subsidiaries

Fully exited 2023–2024

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Mn)

42,3764,3214,8797,25327,391

Revenue growth (%)

40.2-89.812.948.7277.6

Cost of revenue (KRW Mn)

20,6693,0663,4227,77229,333

Gross profit (KRW Mn)

21,7071,2561,457-519-1,941

SG&A (KRW Mn)

19,77016,95622,62923,67012,299

R&D expense (KRW Mn)

4,8596,3057,18211,3184,424

Amortization of goodwill and intangibles (KRW Mn)

1,3811751747181,783

Operating income (KRW Mn)

-6,846-23,092-32,119-39,178-23,614

D&A for EBITDA (KRW Mn)

2,9953,4803,1994,2506,608

EBITDA (KRW Mn)

-3,851-19,613-28,920-34,928-17,006

Interest expense (KRW Mn)

2,4351,0682,0953,4784,269

Interest and investment income (KRW Mn)

2,6911,8002,4211,1942,581

Equity-method earnings (KRW Mn)

-11,511-250-4,002-5,5039,944

Gain or loss on sale of investments (KRW Mn)

4,579-1,953-20,7124,1132,515

Asset writedowns (KRW Mn)

-5090-4-14,351-6,966

Pre-tax income (KRW Mn)

-15,617-22,743-51,152-50,062-20,433

Income tax expense (KRW Mn)

2,723615-2,9411,747-7,921

Net income to company (KRW Mn)

-18,340-25,568-50,042-51,809-12,512

Losses attributed to minority interests (KRW Mn)

2,4401,6991,1182658,991

Net income attributable to parent (KRW Mn)

-15,901-23,869-48,924-51,544-3,521

EPS basic (KRW)

-232.20-344.84-661.31-671.00-45.85

EPS diluted (KRW)

-232.20-345.00-661.31-671.00-45.85

Dividends per share (KRW)

00000

Weighted average shares (M)

6869747777

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

51.229.129.9-7.2-7.1

Operating margin (%)

-16.2-534.4-658.4-540.1-86.2

EBITDA margin (%)

-9.1-453.9-592.7-481.6-62.1

Pre-tax margin (%)

-36.9-526.3-1,048.5-690.2-74.6

Net margin (%)

-37.5-552.4-1,002.8-710.6-12.9

FCF margin (%)

-52.1-903.4-1,140.6-482.4-73.3

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (KRW Mn)

332,927322,613243,116260,465224,109

Cash and equivalents (KRW Mn)

30,95529,96423,01142,93311,584

Short-term investments (KRW Mn)

31,60629,41728,2241,812872

Trading securities (KRW Mn)

59,93922,6531748,8197,144

Cash and short-term investments (KRW Mn)

122,50082,03351,41053,56419,599

Receivables (KRW Mn)

12,3189,3242,82411,69918,295

Inventory (KRW Mn)

8,5785,6771,5559,1816,418

Total current assets (KRW Mn)

144,96598,85456,65275,80245,865

PP&E (KRW Mn)

86,371100,17495,590133,246126,936

Long-term investments (KRW Mn)

79,37590,42779,91526,31929,718

Goodwill (KRW Mn)

2,0262,02603,2357,392

Other intangibles (KRW Mn)

8,1206,4051,6805,4749,195

Short-term debt (KRW Mn)

46,34848,8067,1206,9006,890

Current portion of long-term debt (KRW Mn)

3,7296521,9604,00037,200

Long-term debt (KRW Mn)

24,00520,28229,73842,2000

Lease liabilities total (KRW Mn)

6414583053572,371

Total debt (KRW Mn)

74,72370,19939,12353,45746,461

Net debt (KRW Mn)

-47,777-11,835-12,287-10726,861

Total current liabilities (KRW Mn)

66,51358,52655,54871,17978,942

Total liabilities (KRW Mn)

118,301106,88097,823130,90994,908

Total common equity (KRW Mn)

207,838188,276145,29398,518105,153

Minority interest (KRW Mn)

6,7895,147022,28113,522

Total shareholders' equity (KRW Mn)

214,626215,733145,293129,556129,201

Working capital (KRW Mn)

78,45240,3281,1044,623-33,077

Book value per share (KRW)

3,0722,7321,8981,2811,368

Tangible book value per share (KRW)

2,9222,6101,8761,1681,152

Cash Flow and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Mn)

-11,458-24,405-32,408-25,850-17,413

Capital expenditure (KRW Mn)

-10,607-14,632-23,236-9,138-2,671

Free cash flow (KRW Mn)

-22,065-39,037-55,644-34,988-20,084

FCF per share (KRW)

-322.22-563.98-752.15-455.48-261.52

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE on year-end common equity (%)

-7.7-12.7-33.7-52.3-3.3

ROA on year-end total assets (%)

-4.8-7.4-20.1-19.8-1.6

Current ratio (x)

2.181.691.021.060.58

Debt to total equity (x)

0.350.330.270.410.36

Interest coverage, EBIT/interest (x)

-2.8-21.6-15.3-11.3-5.5

Asset turnover (x)

0.130.010.020.030.12

Days sales outstanding (days)

8662811470123

Days inventory outstanding (days)

15167616643180

Days payables outstanding (days)

3722146119417

Cash conversion cycle (days)

2001,083-284707186

Capital Markets

Metric1Y3Y5Y

Share price change (%)

-41.55-66.98-86.56

Price Point Details

Price pointValue (KRW)DateSource

52-week high

1,667

Trailing as of snapshot

Simply Wall St

52-week low

711

Trailing as of snapshot

Simply Wall St

Close

761

19 Aug 2026

StockAnalysis

Close

885

25 Aug 2026 (YTD −40.48%)

MarketScreener

Close

953

11 Sep 2026

StockAnalysis

Close

873

15 Oct 2026

StockAnalysis

Valuation Snapshot

MultipleValueBasis

Market capitalization

KRW 67.1bn

76.89M shares × KRW 873

Enterprise value

About KRW 115.3bn

Market cap + debt KRW 45.4bn (Jun 2026) − cash and investments KRW 9.4bn (Jun 2026) + minority interest KRW 12.2bn (Mar 2026)

P/E (TTM)

About 156x; not meaningful

TTM EPS KRW 5.58 is driven by non-operating items

EV/Sales (TTM)

About 3.8x

TTM revenue KRW 30.1bn

P/S (current)

2.23x

StockAnalysis

P/B

About 0.67x

Q1 2026 BVPS KRW 1,309

P/TBV

About 0.80x

Q1 2026 TBVPS KRW 1,093

Capital Markets — Analyst consensus

ItemStatus

Analyst consensus

No sell-side coverage identified. Simply Wall St shows no future-growth estimates (score 0/6).

Dividend history and policy

No dividends paid in FY2021–FY2025 in the data reviewed; no stated dividend policy

Buyback authorizations

No formal authorization identified.

Bonus issue

50% bonus share issue decided Dec 2022 (IRGO)

Reverse split

Considered by the market; ruled out by CEO (Jun 2026)

Credit ratings

No Moody's, S&P or Fitch ratings. Domestic ratings not identified.

Debt maturity profile

All long-term borrowings (KRW 37.2bn) fall due within 12 months of 31 Dec 2025; short-term debt KRW 17.6bn (Mar 2026). Instrument-level detail (bank loans vs. bonds, rates, collateral) not publicly disclosed in sources reviewed.

Shares outstanding trend

67.65M (FY2021), 68.91M (FY2022), 76.54M (FY2023), 76.89M (FY2024–Q1 2026). The FY2023 increase reflects the New Lake rights offering.

Analyst Conclusions

Management guidance

  • No quantitative guidance.

  • Qualitative expectations: digital-healthcare monetization from H2 2026 (CEO, Jun 2026); revenue and operating-profit improvement from China royalties (company, Sep 2026); vaccine clinic entry as early as early 2027; long-term enterprise-value aspiration of KRW 1 trillion.

Consensus

None. The stock has no identified sell-side coverage.

Bull case

  1. Platform royalties scale. VIDW gives Invites Loop access to VISTA's Beijing and Shenzhen clinics, about 30 corporate medical sites and about 60 insurers, in a China market growing 24.7% a year. A 5% royalty on a successful roll-out, plus US licensing via Singapore, could create high-margin revenue that the current KRW 30bn revenue base does not reflect.

  2. Asset backing caps the downside. The stock trades at about 0.67x book and about 0.80x tangible book. Land and buildings of about KRW 119bn exceed the market capitalization of about KRW 67bn, so monetizing real estate could resolve the debt maturity wall without dilution.

  3. Ivaltinostat optionality. A positive Phase 2 PFS readout in PDAC maintenance, where no HDAC inhibitor is approved, would re-rate the oncology pipeline. That would require a settlement that restores CG Invites' economic claim on CGP.

Bear case

  1. Liquidity forces dilution. With KRW 9.4bn of cash against about KRW 45bn of debt and negative working capital of −KRW 47bn, a sizable rights issue or asset fire sale is likely within 12 months. That would further erode a share price already down 86.6% over five years.

  2. Operating economics are unproven. Consolidated gross margin is negative (−15.3% TTM) and EBITDA is about −KRW 17.6bn. Reported profit improvements come from equity-method gains, tax credits and minority interests rather than from operations.

  3. The drug-development franchise has been hollowed out. R&D is down 61%, luxeptinib has been returned or deprioritized, other candidates are halted, and the lead asset is controlled in practice by a litigant. What remains is a marginal NSAID (KRW 1.7bn in sales) and a Korean bridging study for a crowded PD-1 market.

Key catalysts and monitorables (next 12 months)

CatalystTimingWhy it matters
Upcoming EGM (e-voting notice 28 Sep 2026)Q4 2026Agenda may involve capital raising, business-purpose changes or a merger.
Refinancing of KRW 37.2bn current borrowingsThrough 2026Determines whether dilution or asset sales are needed
First royalty revenue from VIDWFrom Q4 2026 / 2027First proof that the platform model works
US court developments in the Cho/CGP caseOngoingSets control and economics of ivaltinostat
Ivaltinostat Phase 2 PDAC data (NCT05249101)Timing not disclosedBinary pipeline value event
Camrelizumab Korean bridging study progress2026–2027Possible Korean filing pathway
Acelex Russia export contract—Revenue for the legacy product
Cancer vaccine IND / clinic entryAs early as early 2027Pipeline replenishment
Gross-margin trajectory of the consolidated businessesQuarterlyCore test of the transformation
Related-party dealings with Invites ecosystem entities (GRMC, New Lake Singapore)OngoingGovernance and value-transfer risk

Analyst verdict

CG Invites is no longer the company its listing history suggests. The first technology-track biotech on KOSDAQ and the developer of Korea's 22nd domestic new drug has been reconfigured since mid-2023 by its private-equity owner, New Lake Alliance. It is now a mixed portfolio. AI health solutions, heating patches, automation equipment and genomic testing produced about 92% of FY2025 revenue, while prescription drugs produced about 6%. This reconfiguration has achieved two things. Revenue has scaled to about KRW 30bn on a trailing basis, and cash burn has fallen sharply, with trailing free cash flow of about −KRW 4.6bn against −KRW 55.6bn in FY2023.

It has not yet produced an economically self-sustaining business. Consolidated gross margins are negative. EBITDA losses persist at about KRW 17–18bn a year. The improvement in net income relies on non-operating items. The balance sheet is the immediate constraint. Cash of KRW 9.4bn, KRW 37.2bn of long-term borrowings now current, and working capital of about −KRW 47bn mean that funding decisions in the coming quarters will largely determine shareholder outcomes. The large land and building base, worth more than the equity market value, is the main mitigant. Using it to refinance or sell assets would be preferable to dilutive issuance.

Strategically, the September 2026 China license is the first concrete external validation of the Invites Loop platform. Its modest upfront valuation (about USD 6.88M) and royalty-only upside mean it is a proof point, not yet a value driver. The oncology pipeline holds the most asymmetric upside in ivaltinostat, but that value is impaired by the unresolved US dispute with the founder.

Verdict: The stock is a high-risk, special-situation holding. A low price-to-book multiple sits alongside a credible risk of dilution and unproven unit economics. Conviction should await evidence of positive gross margins and a funded balance sheet.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / notesBackgroundSource

Lee Ho-young (이호영)

CEO (대표이사)

Referred to as President in May 2025 and as CEO from Jan 2026

Prior roles, education and age not disclosed in sources reviewed

Financial News; Dealsite

Oh Soo-yeon (오수연)

Co-CEO (appointed Mar 2024)

Concurrently Vice President of Invites BioCore.

PhD in pharmacology (Dankook University); former principal researcher at Bio Infra; former operations head at Xenia

Dealsite (Jul 2025)

Park Yi-geun (박이근)

Executive Director (전무)

Presented the Jan 2026 shareholder briefing

—

Dealsite

Cho Yoon-sung (조윤성)

Chief Technology Officer

Leads the cancer vaccine program

—

Dealsite

CFO

Name not disclosed in sources reviewed

Bought about 20,000 shares in Nov 2024

—

Dailypharm

“—” = not publicly disclosed.

Major Shareholders

HolderStakeNotes

Insiders

Co-CEO and CFO each bought about 20,000 shares (Nov 2024)

Total insider ownership not disclosed

Competitive Landscape

Competitors by Segment

Business lineNamed competitorsNotes

Pancreatic cancer drug development (Korea-origin)

NeoImmuneTech (NT-I7), MedPacto (vactosertib), Prestige Biopharma (PBP1510), GC Cell (Immuncell-LC combination)

Dailypharm names these as Korean pancreatic-cancer developers alongside CG Invites

HDAC inhibitors (global)

Approved HDAC inhibitors such as vorinostat, romidepsin, belinostat and panobinostat (hematologic indications)

No HDAC inhibitor is approved in PDAC; ivaltinostat's differentiation is in PDAC maintenance

PD-1 in Korean NSCLC

Merck & Co. (Keytruda), BMS/Ono (Opdivo), Roche (Tecentriq, PD-L1), BeiGene (tislelizumab)

Camrelizumab would enter a mature, crowded checkpoint market

Osteoarthritis NSAIDs (Korea)

Pfizer/Viatris (Celebrex, celecoxib) and numerous celecoxib generics; traditional NSAIDs

Acelex sales (KRW 1.7bn) indicate marginal share

Genomics / NGS services (Korea)

Macrogen, GC Genome, EDGC, Theragen Bio

Established domestic players

AI healthcare / medical AI (Korea)

Lunit, VUNO, Kakao Healthcare (unlisted)

Larger, better-funded AI-health specialists

Heating patches, automation equipment

Not identified in sources reviewed

—

Competitor Detail

Metric (latest FY)CG Invites (FY2025)

Revenue (KRW Bn)

27.4

Revenue growth (%)

277.6

Operating margin (%)

-86.2

R&D intensity (% of revenue)

16.2

Company Snapshot

$19.3M

Revenue

71

Employees

2000

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Approved product: Acelex was approved in 2015 as Korea's 22nd domestic new drug, which gives the company regulatory and commercial credentials (Dailypharm).
  • Clean Phase 1b safety data: no ivaltinostat-related serious adverse events across three dose cohorts (28 patients). RP2D set at 250 mg/m². Phase 2 ongoing at about 20 US hospitals (CGP, Jan 2025; Dealsite, Jan 2026).
  • Revenue scale-up: FY2025 revenue reached KRW 27.4bn (+277.6%), and TTM revenue reached KRW 30.1bn by Jun 2026 (S&P).
  • Cost discipline: SG&A fell 48% (KRW 23.7bn to KRW 12.3bn), operating loss narrowed 40% in FY2025, and TTM FCF burn fell to KRW 4.6bn (S&P).
  • Tangible collateral: land of KRW 64.2bn and buildings of KRW 55.1bn on the balance sheet (Mar 2026) can support refinancing or asset sales (S&P).
  • Platform monetization has begun: the first foreign license of Invites Loop (China, Sep 2026) includes a 5% running royalty and gives access to VISTA's network of about 60 insurers and blue-chip corporate clients (Dealsite).

Weaknesses

  • Negative gross margin: −7.1% in FY2025 and −15.3% TTM. The incorporated businesses do not yet cover their direct costs (S&P).
  • Liquidity strain: working capital of −KRW 33.1bn (FY2025) and −KRW 47.3bn (Mar 2026). Cash and investments of only KRW 9.4bn at Jun 2026 against total debt of KRW 45.4bn (S&P). Less than one year of cash runway (Simply Wall St).
  • R&D collapse: R&D fell 60.9% to KRW 4.4bn, the lowest in seven years. Outsourced research fell 84.9% (Dailypharm).
  • Weak drug commercialization: Acelex generated only KRW 1.7bn (6.3% of revenue) a decade after launch. Management attributes this to weak sales capability (Dailypharm; Dealsite).
  • Earnings quality: FY2025 and TTM net results depend on equity-method gains (KRW 9.9bn and KRW 12.9bn), tax credits (KRW 7.9bn) and losses absorbed by minority interests (KRW 9.0bn) (S&P).
  • Disclosure gaps: no segment profitability, geographic data or detailed identity of acquired businesses in the public sources reviewed. This hampers valuation.

Opportunities

  • China digital health growth: a 24.7% CAGR to USD 43.3bn by 2030. The royalty is linked to VIDW's sales (MarketsandMarkets via Dealsite).
  • US licensing of Invites Loop via Singapore: possible synergy with the Guam hospital controlled by the largest shareholder (Dealsite; Dailypharm).
  • Ivaltinostat Phase 2 readout: a positive PFS result in PDAC maintenance (enrollment target 52; primary endpoint PFS) could reprice the asset, provided the control dispute is resolved (PR Newswire).
  • Acelex export: a Russian partner is in negotiation (Dealsite, Jul 2025).
  • Neoantigen vaccine program: colorectal and lung indications targeted for clinic entry as early as early 2027 (Dealsite).
  • KMI and K-Digital Healthcare Alliance: access to a population of about 1.5M annual screenings and a 55-member industry network (Dealsite).

Threats

  • Founder litigation: a USD 100M US federal suit by Cho Joong-myung (filed Oct 2024) over control of CGP. Information sharing on the lead asset has been cut off (Bizhankook; Dailypharm).
  • Pipeline attrition: luxeptinib is not in active development after Hanmi acquired Aptose, and Edaily reports it as returned (Dailypharm; Edaily).
  • Refinancing risk: KRW 37.2bn of long-term debt reclassified as current, plus KRW 17.6bn of short-term debt (Mar 2026) (S&P).
  • Dilution risk: with low cash and a share price down 86.6% over five years, an equity raise is a plausible funding route. Management has ruled out a reverse split but not new issuance (Simply Wall St; Dealsite).
  • Competition: competition from established genomics and medical-AI companies (Macrogen, Lunit, VUNO and others) and from entrenched PD-1 incumbents in NSCLC.
  • Sector sentiment: Korean investors now discount licensing deals without clinical follow-through, after a series of returned licenses in 2026 (Edaily).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Genomic testing service launched Financial NewsNew revenue line (genomic analysis: KRW 4.6bn in FY2025 with "other")
15 May 2025Q1 2025 results: standalone revenue about KRW 1.83bn (vs ~KRW 0.5bn), operating loss about KRW 3.46bn (32% improvement) Financial NewsFirst evidence of cost-out
20 May 2025CAP accreditation for NGS testing announced DailypharmQuality credential for genomics
22–23 May 2025Personalized cancer vaccine data with HLB presented at ASCO 2025 DailypharmVaccine program validation (preclinical)
Jul 2025Co-CEO Oh interview: camrelizumab and ivaltinostat on track; Acelex Russia export negotiation; GRMC acquisition in progress DealsiteStrategy reaffirmation
31 Jul 2025IB Tomato critique: acquisitions such as Hwail did not produce synergies; Acelex commercialization underperformedReputational/strategic scrutiny
8 Sep 2025Largest shareholder acquires management control of GRMC (Guam) DailypharmOverseas smart-hospital platform
8 Jan 2026Shareholder briefing: Singapore hub; ivaltinostat at about 20 US hospitals; camrelizumab 35 patients at 8 sites; vaccine clinic entry targeted for early 2027 DealsitePipeline and platform update
2026 (undated)Bizhankook: competing interpretations of a US court ruling in the CG Invites–Cho dispute; the court said lawful control of CGP depends on whether the stock subscription agreements were performedLegal uncertainty over the key asset
19 Mar 2026FY2025 results: revenue KRW 27.4bn (+277.6%), operating loss KRW 23.6bn, attributable net loss KRW 3.5bn MarketScreener; S&PScale-up via consolidation; losses narrowed
27 Mar 2026AGM held at Magok HQ convention hall Simply Wall StGovernance
8 May 2026Dailypharm: R&D cut 60.9% to KRW 4.4bn; drug sales 6.3% of revenue; luxeptinib not in active development post-Hanmi/Aptose; CGP information flow cut offDrug-developer identity questioned
14 May 2026Q1 2026 results released MarketScreener; S&PQ1 2026 working capital −KRW 47.3bn
21 May 2026Dealsite TV: incorporated businesses drove revenue; technology-fee income dried upEarnings-quality concern
12 Jun 2026CEO Lee rules out a reverse split; plans all-employee stock options at more than 100% premium; expects digital-health monetization in H2 2026 DealsiteCapital-markets stance
26 Jun 2026KMI partnership for K-digital healthcare globalization DealsiteData and channel access
29 Jun 2026EGM: director appointments and articles amendments approved FinancialFilingsBoard change
1 Jul 2026Major shareholding notice filed FinancialFilingsOwnership change
14 Aug 2026H1 2026 results: TTM revenue KRW 30.1bn; TTM attributable net income KRW 0.4bn; Jun 2026 cash KRW 9.4bn S&P via StockAnalysisLiquidity tightening
19 Aug 2026Share price KRW 761, near the 52-week low (KRW 711) StockAnalysisMarket sentiment
25 Aug 2026Share price KRW 885; −40.48% YTD MarketScreener—
11 Sep 2026Share price KRW 953 StockAnalysis—
17 Sep 2026JV agreement with VISTA Clinic Ltd (Hong Kong) DealsiteChina entry vehicle
21 Sep 2026Company disclosure/IR item (IRGO index)—
28 Sep 2026Exclusive China license of Invites Loop and IRS to VIDW (5% royalty; technology valued at about USD 6.88M) DealsiteFirst overseas monetization of the platform
28 Sep 2026EGM electronic-voting notice issued IRGO–
3 Oct 2026Edaily: CG-806 cited among Korean licensed assets returned in 2026 Edaily/NatePipeline value impairment confirmed in press
15 Oct 2026Share price KRW 873 (−1.58% on the day) StockAnalysisMarket cap about KRW 67bn

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue fell from KRW 42,376 Mn in FY2021 to KRW 27,391 Mn in FY2025.
CG Invites Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Revenue42,3764,3214,8797,25327,391
Cost of revenue20,6693,0663,4227,77229,333
Gross profit21,7071,2561,457-519-1,941

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. StockAnalysis.com (S&P Global Market Intelligence data): CG Invites company profile; financials overview; income statement; balance sheet (accessed Oct 2026)
  2. MarketScreener: CG Invites Co., Ltd. stock page and news register
  3. Simply Wall St: CG Invites (KOSDAQ:A083790) stock report
  4. Patsnap Synapse: CG Invites Co., Ltd. organization profile; PanGen Biotech profile
  5. PitchBook: CG Invites company profile; HuonsLifeSciences profile
  6. Citeline/Scrip: CG Invites company page
  7. FinancialFilings.com: CG Invites filings index
  8. IRGO: CG Invites (CrystalGenomics) disclosure index
  9. Dailypharm: "CG Invites R&D cost plunges 60%" (8 May 2026); founder departure (13 Feb 2024); ivaltinostat direct-trial review (18 Oct 2024); company rebuttal (16 Oct 2024); Huons–CG Invites stake deals (11 Nov 2024); insider purchases (21 Nov 2024); post-acquisition restructuring (2 Aug 2023); CrystalGenomics non-core asset sales (2 Jun 2023); Hwail stake exit (20 Nov 2020); CrystalGenomics capital-raising (8 Feb 2021); Hwail acquisition interviews (2013); K-bio pancreatic cancer roundup
  10. Dealsite: China Invites Loop license (28 Sep 2026); Singapore hub briefing (8 Jan 2026); CEO Lee Ho-young interview (12 Jun 2026); KMI partnership (26 Jun 2026); co-CEO Oh Soo-yeon interview (30 Jul 2025); selection and focus (19 Jun 2024)
  11. Dealsite TV: "AI healthcare and hot packs over drug development" (21 May 2026)
  12. Financial News: Q1 2025 results (15 May 2025)
  13. Bizhankook: CG Invites vs founder US court dispute
  14. IB Tomato: acquisitions retrospective (31 Jul 2025)
  15. BizWatch: PanGen acquisition (24 Nov 2022)
  16. Edaily / Nate News: K-bio pulse, returned licenses (3 Oct 2026)
  17. Maeil Business via Daum: FDA Phase 2 clearance (18 Jan 2022)
  18. PR Newswire / BioSpace: CG Pharmaceuticals Phase 2 commencement (17 Nov 2023); CG Pharmaceuticals ASCO GI update (23 Jan 2025)
  19. Clinical Trials Arena: CG Pharmaceuticals Phase 2 start (Nov 2023)
  20. Zonebourse/MarketScreener: Joong-Myung Cho insider profile
  21. Pacific Island Times; Guam Daily Post; Rider Levett Bucknall: Guam Regional Medical City background

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.